Inovio Pharmaceuticals (INO) Net Cash Flow (2010 - 2026)

Inovio Pharmaceuticals has disclosed Net Cash Flow across 17 years of filings, most recently posting $5.3 million for Q2 2026.

• In Q2 2026, Net Cash Flow rose 133.76% year-over-year to $5.3 million; the TTM figure through Jun 2026 stood at $7.2 million (up 171.45% YoY), while the FY2025 annual figure was -$21.5 million, down 141.85% from the prior year.
• Net Cash Flow came in at $5.3 million for Q2 2026 at Inovio Pharmaceuticals, up from -$18.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $44.1 million in Q4 2024 to a low of -$33.9 million in Q3 2023.
• Average Net Cash Flow over 5 years is -$2.2 million, with a median of -$8.3 million recorded in 2022.
• Year-over-year, Net Cash Flow soared 1081.83% in 2024 and tumbled 592.49% in 2025.
• Over 5 years, Net Cash Flow stood at $24.3 million in 2022, then tumbled by 118.47% to -$4.5 million in 2023, then soared by 1081.83% to $44.1 million in 2024, then slumped by 82.54% to $7.7 million in 2025, then tumbled by 31.81% to $5.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $5.3 million in Q2 2026, -$18.0 million in Q1 2026, and $7.7 million in Q4 2025.